Genocea Biosciences, Inc. (NASDAQ:GNCA) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday, August 1st.
Several other analysts have also recently issued reports on GNCA. Zacks Investment Research cut Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, May 30th. Piper Jaffray Companies reiterated an “overweight” rating and set a $18.00 price target (up from $17.00) on shares of Genocea Biosciences in a research report on Tuesday, July 25th. Cowen and Company reiterated an “outperform” rating and set a $40.00 price target on shares of Genocea Biosciences in a research report on Tuesday, July 25th. Finally, Needham & Company LLC upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Monday, July 24th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $16.52.
Genocea Biosciences (NASDAQ:GNCA) traded down 0.74% on Tuesday, reaching $4.01. The company had a trading volume of 134,991 shares. The firm’s market capitalization is $114.78 million. The stock has a 50 day moving average of $5.00 and a 200 day moving average of $5.50. Genocea Biosciences has a 12 month low of $3.28 and a 12 month high of $7.29.
Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by $0.08. On average, analysts anticipate that Genocea Biosciences will post ($1.98) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Genocea Biosciences, Inc. (GNCA) Downgraded to Sell at ValuEngine” was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.com-unik.info/2017/08/19/genocea-biosciences-inc-gnca-downgraded-by-valuengine-updated-updated.html.
In other news, CFO Jonathan Poole sold 45,000 shares of the stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $6.00, for a total transaction of $270,000.00. Following the sale, the chief financial officer now directly owns 84,247 shares in the company, valued at approximately $505,482. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.70% of the stock is currently owned by corporate insiders.
Institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. acquired a new position in shares of Genocea Biosciences during the first quarter worth about $217,000. Keybank National Association OH acquired a new position in shares of Genocea Biosciences during the first quarter worth about $147,000. Ameriprise Financial Inc. raised its position in shares of Genocea Biosciences by 34.1% in the first quarter. Ameriprise Financial Inc. now owns 19,933 shares of the biotechnology company’s stock worth $121,000 after buying an additional 5,068 shares during the period. Segantii Capital Management Ltd acquired a new position in shares of Genocea Biosciences during the first quarter worth about $160,000. Finally, Northpointe Capital LLC raised its position in shares of Genocea Biosciences by 9.6% in the second quarter. Northpointe Capital LLC now owns 1,336,062 shares of the biotechnology company’s stock worth $6,974,000 after buying an additional 117,374 shares during the period. 55.20% of the stock is owned by institutional investors and hedge funds.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Genocea Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Genocea Biosciences Inc. and related companies.